The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations

INTRODUCTION: Tolvaptan, a treatment for autosomal dominant polycystic kidney disease (ADPKD), inhibits vasopressin V2 receptor signaling, which causes aquaretic adverse events (AAEs). The short-term efficacy and tolerability of a once-daily, modified-release (MR) formulation was assessed relative t...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrone, Ronald D., Chapman, Arlene B., Oberdhan, Dorothee, Czerwiec, Frank S., Sergeyeva, Olga, Ouyang, John, Shoaf, Susan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271939/
https://www.ncbi.nlm.nih.gov/pubmed/32518862
http://dx.doi.org/10.1016/j.ekir.2020.03.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271939/
https://www.ncbi.nlm.nih.gov/pubmed/32518862
http://dx.doi.org/10.1016/j.ekir.2020.03.011

Ejemplares similares